Characteristics of analytically confirmed gamma-hydroxybutyrate (GHB) positive patients in the emergency department: presentation, poly-drug use, disposition and impact on intensive care resource utilisation

References

• Ingels A-S, Wille SMR, Samyn N, et al. Screening and confirmation methods for GHB determination in biological fluids. Anal Bioanal Chem. 2014;406(15):3553–3577.
   PubMed Web of Science ®Google Scholar
• Busardo FP, Jones AW. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol. 2015;13(1):47–70.
   PubMed Web of Science ®Google Scholar
• van Amsterdam J, Brunt T, Pennings E, et al. Risk assessment of GBL as a substitute for the illicit drug GHB in the Netherlands. A comparison of the risks of GBL versus GHB. Regul Toxicol Pharmacol. 2014;70(2):507–513.
   PubMed Web of Science ®Google Scholar
• Abanades S, Farré M, Segura M, et al. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann N Y Acad Sci. 2006;1074:559–576.
   PubMed Web of Science ®Google Scholar
• Abanades S, Farré M, Segura M, et al. Disposition of gamma-hydroxybutyric acid in conventional and nonconventional biologic fluids after single drug administration: issues in methodology and drug monitoring. Ther Drug Monit. 2007;29(1):64–70.
   PubMed Web of Science ®Google Scholar
• Brenneisen R, Elsohly MA, Murphy TP, et al. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol. 2004;28(8):625–630.
   PubMed Web of Science ®Google Scholar
• Busardò FP, Jones AW. Interpreting γ-hydroxybutyrate concentrations for clinical and forensic purposes. Clin Toxicol. 2019;57(3):149–163.
   PubMed Web of Science ®Google Scholar
• Liechti ME, Quednow BB, Liakoni E, et al. Pharmacokinetics and pharmacodynamics of γ-hydroxybutyrate in healthy subjects. Br J Clin Pharmacol. 2016;81(5):980–988.
   PubMed Web of Science ®Google Scholar
• Schep LJ, Knudsen K, Slaughter RJ, et al. The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol. Clin Toxicol. 2012;50(6):458–470.
   PubMed Web of Science ®Google Scholar
• Munir VL, Hutton JE, Harney JP, et al. Gamma-hydroxybutyrate: a 30 month emergency department review. Emerg Med Australas. 2008;20(6):521–530.
   PubMed Web of Science ®Google Scholar
• Partridge E, Alfred S, Camilleri A, et al. Establishing the protocols for the South Australian Emergency Department Admission Blood Psychoactive Testing (EDABPT) programme for drug surveillance. Emerg Med Australas. 2021;33(5):883–887.
   PubMed Web of Science ®Google Scholar
• Arunogiri S, Moayeri F, Crossin R, et al. Trends in gamma-hydroxybutyrate-related harms based on ambulance attendances from 2012 to 2018 in Victoria, Australia. Addiction. 2020;115(3):473–479.
   PubMed Web of Science ®Google Scholar
• Dietze P, Horyniak D, Agius P, et al. Effect of intubation for gamma-hydroxybutyric acid overdose on emergency department length of stay and hospital admission. Acad Emerg Med. 2014;21(11):1226–1231.
   PubMed Web of Science ®Google Scholar
• Dietze PM, Cvetkovski S, Barratt MJ, et al. Patterns and incidence of γ-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria. Med J Aust. 2008;188(12):709–711.
   PubMed Web of Science ®Google Scholar
• Chin RL, Sporer KA, Cullison B, et al. Clinical course of γ-Hydroxybutyrate overdose. Ann Emerg Med. 1998;31(6):716–722.
   PubMed Web of Science ®Google Scholar
• Couper FJ, Thatcher JE, Logan BK. Suspected GHB overdoses in the emergency department. J Anal Toxicol. 2004;28(6):481–484.
   PubMed Web of Science ®Google Scholar
• Galicia M, Nogue S, Ãs M. Liquid ecstasy intoxication: clinical features of 505 consecutive emergency department patients. Emerg Med J. 2011;28(6):462.
   PubMed Web of Science ®Google Scholar
• Helander A, Bäckberg M, Beck O. Drug trends and harm related to new psychoactive substances (NPS) in Sweden from 2010 to 2016: experiences from the STRIDA project. PLOS One. 2020;15(4):e0232038.
   PubMed Web of Science ®Google Scholar
• Liakoni E, Walther F, Nickel CH, et al. Presentations to an urban emergency department in Switzerland due to acute γ-hydroxybutyrate toxicity. Scand J Trauma Resusc Emerg Med. 2016;24(1):107–107.
   PubMedGoogle Scholar
• Liechti ME, Kunz I, Greminger P, et al. Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alc Depend. 2006;81(3):323–326.
   PubMed Web of Science ®Google Scholar
• Miró Ò, Nogué S, Espinosa G, et al. Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J Toxicol Clin Toxicol. 2002;40(2):129–135.
   PubMed Web of Science ®Google Scholar
• Alfred S, Haustead D, Mallon J, et al. Results of the South Australian Emergency Department Admission Blood Psychoactive Testing (EDABPT) programme. Med J Aust. 2023 https://doi.org/10.5694/mja2.51907.
   Google Scholar
• Yelland LN, Burns JP, Sims DN, et al. Inter- and intra-subject variability in ethanol pharmacokinetic parameters: effects of testing interval and dose. Forensic Sci Int. 2008;175(1):65–72.
   PubMed Web of Science ®Google Scholar
• Australian Criminal Intelligence Commission. Illicit drug data report 2018–19. Canberra: Commonwealth of Australia; 2020. Available from: acic.gov.au
   Google Scholar
• Australian Criminal Intelligence Commission. Illicit drug data report 2019–20. Canberra: Commonwealth of Australia; 2021. Available from: acic.gov.au.
   Google Scholar
• Camilleri A, Alfred S, Gerber C, et al. Delivering harm reduction to the community and frontline medical practitioners through the South Australian Drug Early Warning System (SADEWS). Forensic Sci Med Pathol. 2021;17(3):388–394.
   PubMed Web of Science ®Google Scholar
• Davey M, Pfeiffer J. Designer Drug Early Warning System (D2EWS) 12-month technical report. DASSA research monograph No. 19, research series. Australia: Drug & Alcohol Services South; 2006.
   Google Scholar
• Sutherland R, Karlsson A, Price O, et al. Australian drug trends 2021: key findings from the national ecstasy and Related Drugs Reporting System (EDRS) interviews. Sydney: UNSW, National Drug and Alcohol Research Council; 2021. Available from: https://ndarc.med.unsw.edu.au/program/drug-trends
   Google Scholar
• Austalian Institute of Health and Welfare. National drug strategy household survey 2019. drug statistics series no. 32. PHE 270. Canberra: AIHW; 2020. Available from: https://www.aihw.gov.au/reports/illicit-use-of-drugs/national-drug-strategy-household-survey-2019
   Google Scholar
• Syse VL, Brekke M, Grimsrud MM, et al. Gender differences in acute recreational drug toxicity: a case series from Oslo, Norway. BMC Emerg Med. 2019;19(1):1–8.
   PubMedGoogle Scholar
• Miró Ò, Waring WS, Dargan PI, et al. Variation of drugs involved in acute drug toxicity presentations based on age and sex: an epidemiological approach based on European Emergency Departments. Clin Toxicol. 2021;59(10):896–904.
   PubMed Web of Science ®Google Scholar
• Smith JL, Soderstrom J, Dawson A, et al. The emerging drugs network of Australia: a toxicosurveillance system of illicit and emerging drugs in the emergency department. Emerg Med Australas. 2022;34(1):58–64.
   PubMed Web of Science ®Google Scholar
• Uys JDK, Niesink RJM. Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature. Drug Alc Review. 2005;24(4):359–368.
   PubMed Web of Science ®Google Scholar
• Barker JC, Harris SL, Dyer JE. Experiences of gamma hydroxybutyrate (GHB) ingestion: a focus group study. J Psychoactive Drugs. 2007;39(2):115–129.
   PubMed Web of Science ®Google Scholar
• Kohrs FP, Mann C, Greenberg R. The use of amphetamine in gamma-hydroxybutyrate overdose: a case report. J Psychoactive Drugs. 2004;36(3):401–402.
   PubMed Web of Science ®Google Scholar
• Caldicott DGE, Chow FY, Burns BJ, et al. Fatalities associated with the use of γ-hydroxybutyrate and its analogues in Australasia. Med J Aust. 2004;181(6):310–313.
   PubMed Web of Science ®Google Scholar
• Griffiths A, Hadley L. The prevalence of gamma-hydroxybutyrate (GHB) in motor vehicle drivers and its co-administration with amphetamine type substances (ATS) in Queensland, Australia (2011–2018). Forensic Sci Int. 2019;303:109958.
   PubMed Web of Science ®Google Scholar
• Australian Criminal Intelligence Commission. National wastewater drug monitoring program-report 10. Canberra: Commonwealth of Australia. Available from: https://www.acic.gov.au/publications/national-wastewater-drug-monitoring-program-reports
   Google Scholar